SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

SK Bioscience and global pharmaceutical giant Sanofi signed an expanded agreement to jointly develop next-generation ...

SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs) targeting ...

Pneumococcal conjugate vaccines (PCVs) are known to provide protection against vaccine serotype pneumococcal pneumonia; uncertainty exists regarding the optimum PCV dosing schedule. Methods ...

Throughout history, immunisation has helped protect millions of children against infectious and life-threatening diseases. Immunisation helps to strengthen your child’s immune system to fight diseases ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

This vaccine candidate is the first-ever PCV containing more than 20 serotypes to enter a phase 3 clinical study in infants and toddlers. Thomas Triomphe Executive Vice President, Vaccines, Sanofi ...

Goldman Sachs rates Vaxcyte a buy with $135 price target, highlighting vaccine platform and pneumonia candidate. Read more ...

In this cluster-randomized controlled trial, it was found that a pneumococcal conjugate vaccine (PCV) schedule involving a ...